IDRx

Stronger Together on #GISTAwarenessDay Did you know 13 people are diagnosed with Gastrointestinal Stromal Tumors (#GIST) every day in the US alone? Today is #GISTAwarenessDay and we stand with the GIST community to raise awareness for this rare cancer. At IDRX, we are dedicated to improving the lives of patients and are proud to be working to advance the standard of care for this serious and underserved cancer. Our goal is to accelerate the development of innovative therapies that bring transformative outcomes for people living with GIST. Learn more at https://lnkd.in/evRaDT4. #GISTLife #GIST #CancerResearch #RareDisease

Our Chief Executive Officer, Tim Clackson spoke with BiotechTV at #ASCO24 about this morning's announcement of the encouraging clinical data from the Phase 1 portion of our ongoing StrateGIST 1 study of IDRX-42. Check it out below.

We’re excited to share today updated preliminary clinical data from the Phase 1 portion of our ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors, or #GIST, at the American Society of Clinical Oncology (ASCO)’s Annual Meeting. Encouraging signs of clinical activity were observed, including a 23% objective response rate across all patients in a heavily pretreated patient population, and a 43% objective response rate across second-line patients. A favorable tolerability profile was also observed. “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx. “Importantly, we believe these efficacy and safety data support our plan to move IDRX-42 rapidly into early lines of therapy, including second-line and front-line, where patients haven’t seen a new treatment option in over 15 years.” Read more: https://lnkd.in/ePCh693j Discover more during our oral presentation at #ASCO24: https://lnkd.in/eiPSyZ9f

Today we welcome David Kerstein, M.D., as our Chief Medical Officer. Dr. Kerstein is an exciting addition to our founding R&D leadership team and joins us with impressive and extensive experience in early- and late-stage oncology drug development, including multiple precision oncology medicines. “This is a unique opportunity to be a part of an exciting company that has the potential to have a meaningful impact on the treatment of GIST patients with IDRX-42, including in early lines of therapy to prevent the emergence of resistance mutations,” said Dr. Kerstein. “IDRx’s progress since its inception is remarkable, and I look forward to working with the exceptional team at IDRx as we prepare for important upcoming clinical milestones.” We look forward to having his guidance and leadership as we advance our lead program, IDRX-42, and aim to improve the lives of patients with GIST. Read more in the release below.

What a sight to see in Times Square! Thank you, Nasdaq, for highlighting Brad Dahms' recent appointment to IDRx chief financial officer on the NASDAQ MarketSite Tower. We're proud to have him on board. 

We’re pleased to share today the appointments of Tim Clackson, Ph.D., as Chief Executive Officer and Brad Dahms as Chief Financial Officer and Chief Business Officer. Both join us from Theseus Pharmaceuticals: Dr. Clackson brings three decades of experience building oncology companies, and Mr. Dahms has deep expertise across strategic growth, business development and financing.    Our co-founder and founding CEO, Ben Auspitz, has transitioned to Chairman of the Company’s Board of Directors. We thank him for the dedication he brought to IDRx, and are thrilled to retain his guidance on our Board. Tim and Brad’s appointments affirm IDRX’s commitment to bring our lead program, IDRX-42, to #GIST patients waiting for better therapies. Read more: https://lnkd.in/eNYCd8gy

We are excited to announce today preliminary clinical data from the dose escalation portion of our ongoing Phase 1 StrateGIST study of IDRX-42 in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The data are being presented at the Connective Tissue Oncology Society 2023 Annual Meeting this week in Dublin, Ireland and demonstrate exciting and clinically meaningful antitumor activity in a highly refractory and difficult to treat GIST patient population. Read more in the release below. #CTOS2023